By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sunovion Pharmaceuticals Inc. 

84 Waterford Drive

Marlborough  Massachusetts  01752  U.S.A.
Phone: 508-481-6700 Fax:



ACADIA Pharmaceuticals, Inc.  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.

Cubist Pharmaceuticals, Inc. 

Company News
Sunovion Pharmaceuticals Inc. And The COPD Foundation Expand COPD Together Campaign To Empower Family Caregivers 11/5/2014 10:43:47 AM
ex scientia Ltd. Partners With Sunovion Pharmaceuticals Inc. To Research New Medicines For Psychiatric Disorders 11/4/2014 10:30:31 AM
CHEST, Sunovion Pharmaceuticals Inc. Encourage COPD Education Among Hispanics During COPD Awareness Month 11/3/2014 9:23:55 AM
Sunovion Pharmaceuticals Inc. Announces Dose Ranging Data From Phase 2 Study Of SUN-101 (Glycopyrrolate) Inhalation Solution For Treatment Of Patients With Moderate-To-Severe Chronic Obstructive Pulmonary Disease (COPD) 10/27/2014 3:04:46 PM
Akorn, Inc. (AKN) Ponies Up $45 Million Cash For Sunovion Pharmaceuticals Inc.'s Xopenex® (levalbuterol HCI) Inhalation Solution 10/1/2014 5:53:07 AM
Sunovion Pharmaceuticals Inc. Announces Data Published In The CHEST Journal From A One-Year, Large Simple Safety Study Evaluating BROVANA® (Arformoterol Tartrate) Inhalation Solution 7/8/2014 7:21:21 AM
FDA Slashes Starting Dose For Sunovion Pharmaceuticals Inc.'s Lunesta; Warns Risk Of Next-Day Impairment 5/15/2014 3:17:45 PM
Sunovion Pharmaceuticals Inc. Release: Once-Daily Aptiom® (Eslicarbazepine Acetate) For The Adjunctive Treatment Of Partial-Onset Seizures Now Available In U.S. Pharmacies 4/7/2014 10:15:05 AM
Sunovion Pharmaceuticals Inc. And Takeda Announce Results From A New Study Showing Maintenance Treatment With Lurasidone Reduced The Risk Of Relapse In Adults With Schizophrenia 3/3/2014 8:36:35 AM
Sunovion Pharmaceuticals Inc. Presents Positive Results From Two Phase 3 Studies Of Once-Daily Aptiom® (Eslicarbazepine Acetate) As Monotherapy Treatment For Partial-Onset Seizures 12/9/2013 10:02:58 AM